Related Experiment Video
Updated: Feb 20, 2026

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
Surgical treatment of active native mitral infective endocarditis: A meta-analysis of current evidence
Jian-Zhou Liu1, Xiao-Feng Li1, Qi Miao1
1Department of Cardiac Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Background:
The native mitral lesion of active infective endocarditis implies a poor prognosis and is associated with adverse short- or long-term results without surgical treatment. Both mitral valvuloplasty (MVP) and mitral valve replacement (MVR) have been performed in the treatment of active native mitral infective endocarditis (ANMIE). However, the outcomes of the two approaches remain unclear. The aim of this study was to systematically review the two procedures with mortality and survival as the primary endpoints.
Methods:
A systematic review of the literature was conducted to identify all relevant studies with comparative data on MVP versus MVR for the treatment of ANMIE. Information on baseline characteristics of patients, operation method, quality of literature, follow-up, and so forth was abstracted using standardized protocols. Pooled odds ratio (OR) or hazard ratio (HR) was calculated and possible publication bias was tested.
Results:
Nine comparative observational studies with a total of 633 patients (MVP = 265, MVR = 368) were identified for qualitative assessment, data extraction, and analysis. The summary OR for operative mortality, comparing repair with replacement, was 0.37 (95% CI 0.0.18-0.80; p = 0.0005). Summary 1- and 5-year HRs for event-free survival were 0.43 (95% CI 0.20-0.92; p = 0.03) and 0.44 (95% CI 0.25-0.77, p = 0.004), respectively (repair vs. replacement). Summary 1- and 5-year survival HRs were 0.51 (95% CI 0.24-1.08; p = 0.08) and 0.55 (95% CI 0.32-0.96; p = 0.004), respectively (repair vs. replacement). No heterogeneity was revealed between studies, and possible publication bias was insignificant.
Conclusions:
This meta-analysis suggests that MVP may be associated with superior postoperative survival outcomes compared with MVR. MVP is desirable, if possible, as a durable alternative to replacement. However, we must consider the influence of different patient characteristics and surgeons' preferences on the choice of surgical approach, and additional powered clinical trials will be required to confirm these findings.
Insights
Mitral valvuloplasty (MVP) may offer better survival outcomes than mitral valve replacement (MVR) for active native mitral infective endocarditis. This meta-analysis suggests MVP is a durable alternative, but further trials are needed.
Area of Science:
- Cardiology
- Cardiac Surgery
- Infectious Diseases
Background:
- Active native mitral infective endocarditis (ANMIE) carries a poor prognosis without surgical intervention.
- Both mitral valvuloplasty (MVP) and mitral valve replacement (MVR) are surgical options for ANMIE.
- Comparative outcomes between MVP and MVR for ANMIE remain unclear.
Purpose of the Study:
- To systematically review and compare the outcomes of MVP versus MVR in patients with ANMIE.
- To evaluate mortality and survival rates as primary endpoints for both surgical approaches.
Main Methods:
- A systematic literature review identified comparative observational studies on MVP versus MVR for ANMIE.
- Data on patient characteristics, surgical methods, and follow-up were extracted.
- Pooled odds ratios (OR) and hazard ratios (HR) were calculated to compare outcomes, with publication bias assessed.
Main Results:
- Nine studies involving 633 patients (265 MVP, 368 MVR) were analyzed.
- MVP was associated with significantly lower operative mortality (OR 0.37, p=0.0005).
- MVP showed improved 1- and 5-year event-free survival (HR 0.43, p=0.03; HR 0.44, p=0.004) and overall survival (HR 0.55, p=0.004 at 5 years).
Conclusions:
- Mitral valvuloplasty (MVP) appears to be associated with superior postoperative survival compared to mitral valve replacement (MVR) in ANMIE.
- MVP is a desirable and potentially more durable alternative to MVR when feasible.
- Further powered clinical trials are necessary to confirm these findings, considering patient characteristics and surgeon preferences.
Related Concept Videos
Endocarditis III: Medical Management
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
Mitral Valve Prolapse II: Assessment and Management
Endocarditis I: Introduction
Endocarditis IV: Nursing Management

